Annual CFI
$11.66 M
+$27.66 M+172.83%
31 December 2023
Summary:
Inhibikase Therapeutics annual cash flow from investing activities is currently $11.66 million, with the most recent change of +$27.66 million (+172.83%) on 31 December 2023. IKT annual CFI is now at all-time high.IKT Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$2.53 M
-$17.10 K-0.67%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly cash flow from investing activities is currently $2.53 million, with the most recent change of -$17.10 thousand (-0.67%) on 30 September 2024. Over the past year, it has dropped by -$14.54 million (-85.19%). IKT quarterly CFI is now -85.19% below its all-time high of $17.06 million, reached on 30 September 2023.IKT Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$358.10 K
-$14.54 M-102.53%
30 September 2024
Summary:
Inhibikase Therapeutics TTM cash flow from investing activities is currently -$358.10 thousand, with the most recent change of -$14.54 million (-102.53%) on 30 September 2024. Over the past year, it has dropped by -$19.09 million (-101.91%). IKT TTM CFI is now -101.91% below its all-time high of $18.74 million, reached on 30 September 2023.IKT TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +172.8% | -85.2% | -101.9% |
| 3 y3 years | - | +100.0% | -100.0% |
| 5 y5 years | +10000.0% | - | - |
IKT Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +172.8% | -85.2% | +112.1% | -101.9% | +98.4% |
| 5 y | 5 years | at high | +172.8% | -85.2% | +112.1% | -101.9% | +98.4% |
| alltime | all time | at high | +172.8% | -85.2% | +112.1% | -101.9% | +98.4% |
Inhibikase Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.53 M(-0.7%) | -$358.10 K(-102.5%) |
| June 2024 | - | $2.54 M(-176.8%) | $14.18 M(-0.0%) |
| Mar 2024 | - | -$3.31 M(+56.5%) | $14.18 M(+21.7%) |
| Dec 2023 | $11.66 M(-172.8%) | -$2.12 M(-112.4%) | $11.66 M(-37.8%) |
| Sept 2023 | - | $17.06 M(+569.1%) | $18.74 M(-197.3%) |
| June 2023 | - | $2.55 M(-143.7%) | -$19.25 M(-11.9%) |
| Mar 2023 | - | -$5.84 M(-217.6%) | -$21.84 M(+36.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$16.01 M(<-9900.0%) | $4.96 M(-123.7%) | -$16.01 M(-23.7%) |
| Sept 2022 | - | -$20.93 M(>+9900.0%) | -$20.97 M(>+9900.0%) |
| June 2022 | - | -$43.10 K(<-9900.0%) | -$43.10 K(<-9900.0%) |
| Mar 2022 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2021 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2021 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2021 | - | $0.00 | $0.00 |
| Dec 2018 | $87.10 K | - | - |
FAQ
- What is Inhibikase Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual CFI year-on-year change?
- What is Inhibikase Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly CFI year-on-year change?
- What is Inhibikase Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM CFI year-on-year change?
What is Inhibikase Therapeutics annual cash flow from investing activities?
The current annual CFI of IKT is $11.66 M
What is the all time high annual CFI for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual cash flow from investing activities is $11.66 M
What is Inhibikase Therapeutics annual CFI year-on-year change?
Over the past year, IKT annual cash flow from investing activities has changed by +$27.66 M (+172.83%)
What is Inhibikase Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of IKT is $2.53 M
What is the all time high quarterly CFI for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly cash flow from investing activities is $17.06 M
What is Inhibikase Therapeutics quarterly CFI year-on-year change?
Over the past year, IKT quarterly cash flow from investing activities has changed by -$14.54 M (-85.19%)
What is Inhibikase Therapeutics TTM cash flow from investing activities?
The current TTM CFI of IKT is -$358.10 K
What is the all time high TTM CFI for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM cash flow from investing activities is $18.74 M
What is Inhibikase Therapeutics TTM CFI year-on-year change?
Over the past year, IKT TTM cash flow from investing activities has changed by -$19.09 M (-101.91%)